InterMune to Provide Overview of Corporate Strategy; Sees R&D Expenses of $85-$95 Million

InterMune ITMN will outline the company's corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26. InterMune will conduct a live webcast of the presentations beginning at 8:30 a.m. EDT. InterMune also will discuss at the Analyst Day its 2011 financial guidance for operating expenses. The company today provided its forward-looking expense guidance for 2011 as follows: R&D expense: anticipated to be in a range of approximately $85 to $95 million. SG&A expense: anticipated to be in a range of approximately $65 to $75 million.